Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Puma Biotechnology Inc, 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Puma Biotechnology Inc June 11, 202696.5%
-
BioCardia Inc. December 2, 202594.7%
-
Puma Biotechnology Inc June 11, 202598.3%
-
Puma Biotechnology Inc June 18, 202498.2%
-
Puma Biotechnology Inc June 13, 202397.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 12, 2026 | Puma Biotechnology Inc | Open-market sale | −22,000 | $7.22 | $158,840 |
| Jun 11, 2026 | Puma Biotechnology Inc | Grant or award | +27,000 | — | — |
| Feb 23, 2026 | SiNtx Technologies Inc. | Open-market purchase | +1,000 | $2.91 | $2,910 |
| Aug 26, 2025 | SiNtx Technologies Inc. | Open-market purchase | +3,000 | $3.59 | $10,770 |
| Jun 13, 2025 | Puma Biotechnology Inc | Open-market sale | −22,000 | $3.40 | $74,800 |
| Jun 11, 2025 | Puma Biotechnology Inc | Grant or award | +27,000 | — | — |
| Jun 18, 2024 | Puma Biotechnology Inc | Grant or award | +27,000 | — | — |
| Jun 13, 2024 | Puma Biotechnology Inc | Open-market sale | −22,000 | $3.34 | $73,480 |
| Jun 13, 2023 | Puma Biotechnology Inc | Open-market sale | −22,000 | $3.45 | $75,900 |
| Jun 13, 2023 | Puma Biotechnology Inc | Grant or award | +27,000 | — | — |
Questions about Jay M. Moyes
What boards is Jay M. Moyes on?
Jay M. Moyes sits on the boards of BioCardia Inc., Puma Biotechnology Inc and SiNtx Technologies Inc.
How long has Jay M. Moyes served on boards?
Our records show at least 8 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.